IOVA News and Press, Iovance Biotherapeutics Inc. From 04/20/23

2023-04-20 09:45:00 ET After a dreadful 2022, growth stocks have started to rebound in 2023. The tech-heavy Nasdaq Composite has gained a healthy 15.4% so far this year. Still, scores of beaten-down tech and biotech stocks remain woefully undervalued right now. As a result, there is a s...

2023-04-19 00:43:05 ET Summary Iovance completed its biologics license application (BLA) for its TIL therapy lifileucel before the end of March 2023 setting the stage for possible commercialization after FDA approval. IOVA's cash position of $471.8 million at the moment is suffici...

2023-03-27 15:56:55 ET Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were up 11% Monday afternoon after the late-stage biotech company announced on Friday that it had filed a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for its therapy Lifileu...

2023-03-27 08:52:49 ET First Citizens BancShares ( FCNCA ) +39% deal for First Citizens to buy Silicon Valley Bank. First Republic Bank ( FRC ) +24% inks deal for First Citizens to buy Silicon Valley Bank. Baudax  ( BXRX ) +26% Announces Posi...

2023-03-24 18:22:48 ET Iovance Biotherapeutics ( NASDAQ: IOVA ) is up 13% in after-hours trading Friday after reporting it has completed its rolling Biologics License Application for lifileucel for melanoma. Lifileucel, a tumor infiltrating lymphocyte therapy...

2023-03-24 17:28:03 ET Gainers: BridgeBio Pharma ( BBIO ) +14% . Iovance Biotherapeutics ( IOVA ) +10% . Iris Energy  ( IREN ) +5% . Alphabet ( GOOGL ) +4% . Zions Bancorporation  ( ZION ) +3% . Losers: CRISPR T...

SAN CARLOS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced it has completed its rolling Biologics License Application (BLA) submission to the U.S. Foo...

2023-03-21 07:43:24 ET A top FDA official said Monday that the agency needs to consider accelerated approval, a regulatory avenue commonly used to expedite the market entry of cancer drugs, for gene therapies. Dr. Peter Marks, who heads the FDA's biologics unit, said that the agency...

Iovance Biotherapeutics, Inc. (IOVA) Q4 2022 Earnings Conference Call February 28, 2023 16:30 ET Company Participants Sara Pellegrino - Senior Vice President, Investor Relations and Corporate Communications Fred Vogt - Interim President and Chief Executive Officer Igor...

Iovance Biotherapeutics press release ( NASDAQ: IOVA ): Q4 GAAP EPS of -$0.64 in-line. Iovance had $478.3 million in cash, cash equivalents, investments and restricted cash at December 31, 2022, compared to $602.1 million at December 31, 2021. Research...